Urology Department, Tanta Faculty of Medicine, Tanta, Egypt,
Urology Department, Tanta Faculty of Medicine, Tanta, Egypt.
Urol Int. 2021;105(7-8):568-573. doi: 10.1159/000513074. Epub 2021 Feb 1.
To compare the efficacy and safety of silodosin versus tamsulosin as medical expulsive therapy for stones of lower-third ureter in children.
This prospective single-blind placebo-controlled randomized study included 167 pediatric patients who presented with distal ureteric stone (DUS) less than 1 cm. Patients were randomized into 3 groups; group I received silodosin 4 mg once daily, and group II received tamsulosin 0.4 mg while those in group III had placebo. The side effects of the used drugs, both rate and time of stone expulsion, and number of pain episodes were compared among the study groups for a maximum of 4 weeks.
Follow-up data of our patients after treatment revealed that the stone expulsion rate was significantly higher and the time to stone expulsion was significantly shorter in group I (89.3%, 12.4 ± 2.3 days) and group II (74.5%, 16.2 ± 4.2 days) compared to group III (51.8%, 21.2 ± 5.6). However, a statistically significant difference between silodosin and tamsulosin groups in favor of the former one was reported regarding the 2 studied items. Meanwhile, pain episodes requiring analgesia were statistically fewer in group I and II in contrast to placebo group. Adverse events were comparable among all groups.
Silodosin provides significantly better stone expulsion rate and shorter expulsion time than tamsulosin for treatment of DUS. Both medications showed good safety profiles in children. However, further studies are required on a larger scale to confirm our results. Assessment of drug safety on younger age-group is still needed.
比较索利那新与坦索罗辛作为医学排石疗法治疗儿童下三分之一段输尿管结石的疗效和安全性。
这是一项前瞻性、单盲、安慰剂对照、随机研究,纳入了 167 名患有下段输尿管结石(DUS)<1cm 的儿科患者。患者被随机分为 3 组:I 组给予索利那新 4mg 每日 1 次,II 组给予坦索罗辛 0.4mg,III 组给予安慰剂。比较研究组之间药物的副作用、结石排出率和时间以及疼痛发作次数,最长随访 4 周。
治疗后患者的随访数据显示,I 组(89.3%,12.4±2.3 天)和 II 组(74.5%,16.2±4.2 天)的结石排出率显著高于 III 组(51.8%,21.2±5.6 天),且结石排出时间也显著缩短。然而,与坦索罗辛组相比,索利那新组在这 2 项研究指标上具有统计学显著优势。同时,与安慰剂组相比,I 组和 II 组需要镇痛的疼痛发作次数明显减少。所有组之间的不良事件相当。
与坦索罗辛相比,索利那新能显著提高 DUS 的结石排出率和缩短排出时间。这两种药物在儿童中均表现出良好的安全性。然而,仍需要更大规模的研究来证实我们的结果。需要进一步评估药物在更年轻年龄组的安全性。